Dysport
ApprovedBiologic
IpsenDysport is one of 145 biologic programs targeting Cervical Dystonia. It is currently in Approved.
7
Indications
15
Total Trials
2
Active Trials
144
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
82 competitors in Cerebral Palsy
#DrugCompanyPhaseTrials
1Ingrezza
Neurocrine BiosciencesPhase 3
Dysport
IpsenApproved
XEOMIN
MMerz Pharmaceuticals GmbH
Phase 3
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Advil
KKenvue Brands
Phase 3
Cyklokapron
AAmring
Phase 3
Botulinum Toxin
MMeshalkin Research Institute of Pathology of Circulation
Phase 3
Fosamax
Mylan Pharmaceuticals IncPhase 3
PROCRIT
WWim Janssens
Phase 2
Osmitrol
BB. Braun Medical Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Safety and Efficacy1 trial
Spasticity1 trial
Randomized Controlled Trial1 trial
8 more indications
Cervical Dystonia1 trial
Dystonia1 trial
Abobotulinum Toxin and Neubotulinum Toxin Injection in Cerivical Dystonia
Completed·DDepartment of Medical Services Ministry of Public Health of Thailand·Phase 3·NCT03805152·52 enrolled
Cerebral Palsy1 trial
Effect of Dysport Injections on Energy Expenditure and Walking Efficiency in Children With Cerebral Palsy
Completed·—·Phase 3·NCT03469999·12 enrolled
Skin Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Dysport. EMBL-EBI & Wellcome Sanger Institute.
- [4]